ALT: Pemvidutide advances in late-stage liver disease trials, emphasizing dual action and strong tolerability

Management outlined progress in late-stage liver disease trials, highlighting pemvidutide's dual mechanism, strong phase II data in MASH and AUD, and robust financials supporting execution. Key differentiators include tolerability, adherence, and muscle preservation, with major data readouts expect…